Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors

被引:8
作者
Donepudi, M [1 ]
Quach, DD [1 ]
Mokyr, MB [1 ]
机构
[1] Univ Illinois, Dept Biochem & Mol Biol M C536, Chicago, IL 60612 USA
关键词
tumor bearers; CTL activity; CD40; ligation; costimulatory molecules;
D O I
10.1007/s002620050560
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent studies have demonstrated the importance of CD40/CD154 (CD40L) interactions for the generation of cell-mediated antitumor immune responses. Here we show that signaling via CD40 (through the use of the activating anti-CD40 mAb, 1C10) can actually promote the in vitro generation of CTL activity by CD8(+) splenic T cells from mice bearing a large MOPC-315 tumor. Anti-CD40 mAb had to be added at the initiation of the stimulation cultures of tumor-bearing splenic cells in order to realize fully its potentiating activity for cytotoxic T lymphocyte (CTL) generation, suggesting that signaling through CD40 is important at the inductive stage of antitumor cytotoxicity. Moreover, anti-CD40 mAb was found to enhance the expression of the B7-2 (CD86) and, to a lesser extent, the B7-1 (CD80) costimulatory molecules on B220(+) cells (i.e., B cells), and B7-2 and, to a lesser extent, B7-1 molecules played an important role in the potentiating effect of anti-CD40 mAb for CTL generation by tumor-bearer splenic cells. Furthermore, B220(+) cells were found to be essential for the potentiating effect of anti-CD40 mAb, as depletion of B220(+) cells at the inductive stage completely abrogated the ability of anti-CD40 mAb to enhance CTL generation. Thus, signaling through CD40 enhances CTL generation by CD8(+) T cells from tumor-bearing mice by a mechanism that involves the up-regulation of B7-2 and, to a lesser extent, B7-1 expression on B220(+) cells.
引用
收藏
页码:153 / 164
页数:12
相关论文
共 38 条
[1]   PRESENCE OF AN ENLARGED POOL OF MOPC-315-SPECIFIC CYTOTOXIC LYMPHOCYTE-T PRECURSORS IN THE THYMUSES OF MICE THAT ERADICATED A LARGE MOPC-315 TUMOR AS A CONSEQUENCE OF LOW-DOSE MELPHALAN THERAPY [J].
BARTIK, MM ;
AHN, MC ;
BAUMGARTEL, BA ;
HENDRICKS, RL ;
MOKYR, MB .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 32 (03) :143-153
[2]   Help for cytotoxic-T-cell responses is mediated by CD40 signalling [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Flavell, RA ;
Miller, JFAP ;
Heath, WR .
NATURE, 1998, 393 (6684) :478-480
[3]   CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8(+) CTL response [J].
Borrow, P ;
Tishon, A ;
Lee, S ;
Xu, JC ;
Grewal, IS ;
Oldstone, MBA ;
Flavell, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (05) :2129-2142
[4]   CD40 ligand is required for protective cell-mediated immunity to Leishmania major [J].
Campbell, KA ;
Ovendale, PJ ;
Kennedy, MK ;
Fanslow, WC ;
Reed, SG ;
Maliszewski, CR .
IMMUNITY, 1996, 4 (03) :283-289
[5]   ACTIVATION OF HUMAN DENDRITIC CELLS THROUGH CD40 CROSS-LINKING [J].
CAUX, C ;
MASSACRIER, C ;
VANBERVLIET, B ;
DUBOIS, B ;
VANKOOTEN, C ;
DURAND, I ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1263-1272
[6]  
CONSTANT S, 1995, J IMMUNOL, V155, P3734
[7]  
Falcone M, 1998, J IMMUNOL, V161, P1163
[8]  
GORELIK L, 1995, J IMMUNOL, V154, P3941
[9]   Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the sc tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome [J].
Gorelik, L ;
Mokyr, MB .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 41 (06) :363-374
[10]  
Gorelik L, 1996, J IMMUNOL, V156, P4298